This report illustrates how our portfolio companies contributed to science, innovation and the clinical
development of new medicines in 2023. It also sets out how they performed across environmental, social and governance (ESG) factors. As referred to in the Sustainable Finance Disclosure Regulation (SFDR) Article 8, we have categorized our funds as financial products which promote environmental or social characteristics.
This categorization was primarily driven by our focus on impacting the future of medicine and the specific characteristics of early-stage life sciences companies. Our investors increasingly request ESG and impact-related data for their own regulatory reporting, portfolio monitoring and benchmarking. They use different reporting templates and request more granular information, sometimes directly from portfolio companies. In response to these developments, Forbion joined forces with eleven life sciences-focused VC managers to standardize ESG reporting and reduce the burden on portfolio companies. Through initiatives such as this, we continue to advance our approach to impact and ESG integration to align with industry standards, regulatory requirements and the expectations of our investor